Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05643118 · ClinicalTrials.gov registry record · Phase 1
Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
A Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Olix Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 5
- Study locations
NCT05643118: Completed Phase 1 study of Neovascular Age-related Macular Degeneration, sponsored by Olix Pharmaceuticals.
NCT05643118 is a Phase 1 study of Neovascular Age-related Macular Degeneration that has completed, run by Olix Pharmaceuticals. The registered enrollment target is 21 participants, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05643118, a Phase 1 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Olix Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending dose study. The primary objective is to evaluate the safety and tolerability of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD. The exploratory objectives are to evaluate the preliminary efficacy of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD, and to evaluate the pharmacokinetics (PK) of single and multiple intravitreal injection(s) of OLX10212 in patients with neovascular AMD.
Primary Outcome
Visual acuity using an ETDRS chart
Conditions Studied
Interventions
- GENETIC OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)
Study Locations (5)
California
- California Retina Consultants - Santa Maria
Illinois
- University Retina - Oak Forest
Missouri
- The Retina Institute - St Louis
New York
- Ophthalmic Consultants of the Capital Region - Troy
Texas
- Texas Retina Consultants - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2025-11-10 |
| Phase | Phase 1 |
What the finished NCT05643118 record still lists
NCT05643118 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 408-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) is the first listed.
NCT05643118 lists 5 locations in 5 states (California, Illinois, Missouri).
Frequently Asked Questions
What is clinical trial NCT05643118 about?
NCT05643118 is a clinical study titled "Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration". This is a Phase 1, multicenter, open-label, single- and multi-dose, dose-escalating study of OLX10212 in patients with neovascular age-related macular degeneration (AMD). This study is composed of 2 parts: Part A and Part B. Part A is a single ascending dose study, and Part B is a multiple ascending...
What is the current status of trial NCT05643118?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2023-01-04. Estimated completion is 2025-11-10.
What conditions does trial NCT05643118 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05643118?
The interventions under investigation include: OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA) (GENETIC).
Who is sponsoring clinical trial NCT05643118?
This trial is sponsored by Olix Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05643118 being conducted?
This trial has 5 study locations across California, Illinois, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05643118's enrollment target sits among peer trials
21 28th of 33 higher than 4 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
ACTIVE NOT RECRUITING · Phase 1
-
Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
COMPLETED · Phase 1
-
Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI